CanChip and Glint Lab Announce Strategic Collaboration to Advance Tumor-on-Chip Drug Discovery Models

CanChip and Glint Lab Announce Strategic Collaboration to Advance Human-Based Drug Discovery Models and Bridge Translational Gaps

Potsdam, Germany and San Diego, CA – June 10, 2026– CanChip, a pioneering biotech innovator in tumor-on-a-chip platforms, and Glint Lab, a leading preclinical contract research organization (CRO) specializing in digital pathology, today announced a strategic collaboration to develop robust, trustworthy human-based drug discovery models. This partnership merges CanChip’s expertise in replicating the human tumor microenvironment with Glint Lab’s AI-driven digital pathology capabilities, aiming to enhance drug screening accuracy, reduce reliance on animal models, and accelerate the transition from preclinical testing to clinical trials.

Key highlights of the collaboration include:

Integrated Physiological and Digital Expertise: CanChip delivers cutting-edge tumor-on-a-chip technology that mimics the human tumor microenvironment, while Glint Lab applies AI-powered image analysis and precision histopathology to validate model performance against native tissues.
Ethical and Efficient Drug Discovery: The partnership prioritizes human-centric alternatives to animal testing, improving biological relevance and translational success rates for biopharmaceutical researchers.
Bridging the Preclinical-Clinical Divide: Through comparative analysis at the tissue level, the collaboration addresses key gaps in model reliability, enabling more predictive data for clinical outcomes.

“Our collaboration with CanChip is built on the shared mission of reducing animal testing while providing the biopharmaceutical industry with superior alternatives. By merging our AI-driven histopathology services with CanChip’s innovative tumor-on-a-chip platforms, we are helping researchers move toward a more efficient and human-centric drug discovery process.”

Misagh Naderi, CEO of Glint Lab

This strategic collaboration underscores both companies’ commitment to visionary innovation in preclinical research, delivering tools that empower the industry to achieve faster, more ethical, and reliable drug development.

At CanChip, we believe human-relevant models should provide answers, not just data. Partnering with Glint Lab allows us to further validate our platforms and accelerate the transition toward more predictive, animal-free drug discovery. said

Ghazaleh Madani, CEO of CanChip.

About CanChip

CanChip, based in Potsdam, Germany, is a biotech innovator developing customizable, 3D-printed tumor-on-a-chip and microphysiological platforms designed to replicate complex human tissue environments with high biological relevance. By integrating relevant cell types and enabling long-term cultures, CanChip generates predictive, human-relevant data to support drug discovery, disease modeling, and translational research. Rather than offering standardized systems, CanChip designs tailored solutions to address specific scientific challenges, helping researchers improve decision-making while reducing reliance on animal models. For more information, visit canchip.org

About Glint Lab

Glint Lab, headquartered in San Diego, California, is a preclinical CRO excelling in precision histopathology, AI-driven digital pathology, multiplex assays, and spatial biology. Glint Lab transforms complex biological data into actionable insights for advanced drug discovery. For more information, visit glintlab.com